Q-omics provides the consensus-scored ANKRD10 profile across patient tissues and cancer cell-line models. ANKRD10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ANKRD10 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ANKRD10 protein abundance shows 23,734 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, COAD, and PDAC as cancer lineages where ANKRD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD10 survival associations across molecular data types. ANKRD10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD10 RNA expression–survival associations across cancer types. High ANKRD10 expression shows unfavorable associations in ACC, KIRC, LGG, UVM and LIHC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ANKRD10 RNA expression.
This table summarizes ANKRD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD10 shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, HNSC, STAD and LIHC. The COAD box plot shows higher ANKRD10 RNA expression in tumor versus normal tissue (log2 FC = +1.330, t-test p < 0.001).
This table shows molecular features associated with ANKRD10 in patient tissues and cancer cell lines. In patient samples, ANKRD10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
